// App-Quantinova.ai

e16504 : Retrospective analysis of prognostic factors for survival in metastatic castration-resistant prostate cancer patients (mCRPC) treated with abiraterone.

Researchers

Presenter

  • Krisztina Biro

Principal Investigators

  • Barna Budai

  • Marta Szonyi

  • Istvan Bodrogi

  • Zsofia Kuronya

  • Fruzsina Gyergyay

  • Krisztian Nagyivanyi

  • Lajos Geczi

Medical Centers

  • National Institute of Oncology, Budapest, Hungary

  • St. Margaret Hospital, Budapest, Hungary

Locations

  • Hungary

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved